Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers in lung oncology.

Pulmonary pharmacology & therapeutics - 1 Dec 2010

Rosell Rafael, Vergnenegre Alain, Liu Baorui, Cobo Manuel, Massuti Bartomeu, Wei Jia, Molina Miguel Angel, Costa Carlota, Queralt Cristina, Taron Miquel

Abstract excerpt

The survival of advanced non-small-cell lung cancer patients is short in spite of advances in new combination chemotherapy regimens. The benefit of adding antiangiogenic drugs and/or EGFR inhibitors is unclear. For the vast majority of patients without EGFR mutations, treatment approaches based on customization should be pursued. BRCA1 is central to the repair of DNA damage and is an important modulator of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Precision Medicine
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiogenesis Inhibitors

Share to Antineoplastic Agents

Share to BRCA1 Protein

Share to Carcinoma, Non-Small-Cell Lung

Share to DNA Damage

Share to Endonucleases

Source

Identifiers

PMID: 20471486
DOI: 10.1016/j.pupt.2010.05.003

Genes

EGFR
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers in lung oncology.PMID 20471486Read ↗

Biomarkers in lung adenocarcinoma: a decade of progress.Semantic proximity Read ↗

Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.Semantic proximity Read ↗

Emerging Biomarkers in Personalized Therapy of Lung Cancer.Semantic proximity Read ↗

Lung cancer biomarkers, targeted therapies and clinical assays.Semantic proximity Read ↗

Usefulness of predictive tests for cancer treatment.Semantic proximity Read ↗

Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.Semantic proximity Read ↗

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.Semantic proximity Read ↗

Genetics and biomarkers in personalisation of lung cancer treatment.Semantic proximity Read ↗

Lung cancer genotype-based therapy and predictive biomarkers: present and future.Semantic proximity Read ↗

Biomarkers in bronchopulmonary cancer.Semantic proximity Read ↗

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.Semantic proximity Read ↗

[Biomarker analysis from a pathologist's view. Founding the rationale for personalised treatment of lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.